Long-term effects of octreotide therapy on in-stent restenosis

Heart and Vessels

Volumn 18, Issue 3, 2003, Pages 130-135

  Kursaklioglu, Hurkan ^a   Iyisoy, Atila ^a   Amasyali, Basri ^a   Barcin, Cem ^a   Kose, Sedat ^a   Celik, Turgay ^a   Kilic, Ayhan ^a   Ozturk, Cengiz ^a   Demirtas, Ertan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

In stent restenosis; Neointimal hyperplasia; Octreotide

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIARRHEAL AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; NITRATE; OCTREOTIDE; PANCREAS ENZYME; PLACEBO; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0043064102     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-003-0702-3     Document Type: Article

References (28)

1. Antonioucci D, Valenti R, Santora GM (1998) Restenosis after coronary stenting in current clinical practice. Am Heart J 135:510-518
2. Epstein SE, Speir E, Ungar EF, Guzman RJ, Finkel T (1994) The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol 23:1278-1288
3. Colas B, Combillau C, Buscail L, Zeggari M, Esteve JP, Lautre V, Thomas F, Vaysse N, Susini C (1992) Stimulation of membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem 207:1017-1024
4. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H (1994) Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91:2315-2319
5. Von Essen R, Ostermaier R, Grube E, Maurer W, Tebbe U, Erbel R, Roth M, Oel W, Brom J, Weidinger G (1997) Effects of octreotide treatment on restenosis after coronary angioplasty: results of VERAS study. VErringerung der Restenoserate nach Angioplastie durch ein Somatostatin-analogon. Circulation 96: 1482-1487
6. Eriksen UH, Amtorp O, Bagger JP, Emanuelsson H, Foegh M, Henningsen P, Saunamaki K, Schaeffer M, Thayssen P, Orskov H (1995) Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J 130:1-8
7. Kent KM, Williams DO, Cassagneau B (1993) Double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty (abstract). Circulation 88 (suppl I): 506
8. Emanuelsson H, Beatt KJ, Bagger JP, Balcon R, Heikkila J, Piessens J, Schaeffer M, Suryapranata H, Foegh M, for the European Angiopeptin Study Group (1995) Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis. Circulation 91:1689-1696
9. Hong MK, Kent KM, Mehran R (1997) Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. Circulation 95:449-454
10. Demirtaş E, Saǧ C, Kurşaklioǧlu H, Uzun M, Uzbay T, Tore HF, Kose S, Genc C, Demirkan D (1998) Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy. Jpn Heart J 39:173-181
11. Mintz GS, Pichard AD, Kent KM, Settler LF, Popma JJ (1995) Endovascular stents reduce restenosis by eliminating geometrical arterial remodeling: a serial IVUS Study (abstract). J Am Coll Cardiol 25 (suppl A):36A
12. Hoffman R, Mintz GS, Dussaillant GR (1996) Patterns and mechanisms of in-stent restenosis. A serial IVUS study. Circulation 94:1247-1254
13. Dussailant GR, Mintz GS, Pichard AD (1995) Small stent size and intimal hyperplasia contribute to restenosis. A volumetric IVUS analysis. J Am Coll Cardiol 26:720-724
14. Kunishima T, Musha H, Eto F, Iwasaki J, Masui Y, So T, Nakamura T, Oohama N, Murayam M (1997) A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 19:1058-1066
15. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM (2000) Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85:962-968
16. Peters S, Götting B, Trümmel M, Rust H, Brattström A (2001) Valsartan for prevention of restenosis after stenting of type B2/C lesions: the Val-PREST Trial. J Invas Cardiol 13:93-97
17. Zhu B, Zhao G, Witte DP, Hui DY, Fagin JA (2001) Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology 142: 3598-3606
18. Clemmons DR, Van Wyk JJ (1990) A factor contained in plasma is required for IGF binding protein-1 to potentiate the effect of IGF-I on smooth muscle cell DNA synthesis. J Cell Physiol 145:129-135
19. Delafontaine P, Lou H, Alexander RW (1991) Regulation of insulin like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension 18:742-747
20. Liau G, Chan LM (1989) Regulation of extracellular matrix RNA levels in cultured smooth muscle cells. Relationship to cellular quiescence. J Biol Chem 264:10315-10320
21. Howell M, Trowbridge R, Foegh M (1991) Effects of delayed angiopeptin treatment on myointimal hyperplasia following angioplasty (abstract). J Am Coll Cardiol 17:181A
22. Santonian EC, Schneider JE, Gravanis MB, Foegh M, Tarazona N, Cipolla GD, King SB (1993) Angiopeptin inhibits neointimal hyperplasia after angioplasty in porcine coronary arteries. Circulation 88:11-14
23. Ellis SG, Savage M, Fischman D (1992) Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience. Circulation 86:1836-1844
24. Kastrati A, Schömig A, Elezi S (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428-1436
25. Fingerle J, Faulmuller A, Muller G (1992) Pituitary factors in blood plasma are necessary for smooth muscle cell proliferation in response to injury in vivo. Arterioscler Thromb 12:1488-1495
26. Eriksen UH, Amtorp O, Bagger JP (1993) Continuous angiopeptin infusion reduces coronary restenosis following balloon angioplasty (abstract). Circulation 88 (suppl I):594
27. Moussa I, Moses J, Di Mario C, Albiero R, De Gregorio J, Adamian M, Di Francesco L, Colombo A (1999) Does the specific intravascular ultrasound criterion used to optimize stent expansion have an impact on the probability of stent restenosis? Am J Cardiol 83:1012-1017
28. Goods CM, Al Shaibi KF, Yadav SS, Liu MW, Negus BH, Iyer SS, Dean LS, Jain SP, Baxley WA, Parks JM, Sutor RJ, Roubin GS (1996) Utilization of the coronary balloon expandable coil stent without anticoagulation or intravascular ultrasound. Circulation 93:1803-1808